The receptor tyrosine kinase Tie 1 is expressed and activated in epithelial tumour cell lines

The receptor tyrosine kinase Tie1 is expressed primarily in vascular endothelial cells. The receptor has also been detected in epithelial tumours in breast, thyroid and gastric cancers and in tumour cell lines where it appears as a 45 kDa truncated receptor fragment. In this study, we show that in addition to truncated Tie1, breast and colon tumour cell lines express a full-length Tie1 holoreceptor. In contrast to the situation in endothelial cells, Tie1 truncation is not activated by phorbol esters and generation of truncated Tie1 does not occur via a metalloprotease-inhibitor sensitive mechanism. Examination of the phosphorylation status of Tie1 revealed both the holoreceptor and truncated receptor to be constitutively activated in MCF-7 cells. These data indicate that Tie1 expressed in epithelial tumour cell lines is present in holoreceptor and truncated forms, and in MCF-7 cells both forms are constitutively phosphorylated and competent to signal. Our findings suggest therefore that anti-angiogenic strategies targeting the angiopoietin/Tie system in tumour microvasculature could also have additional direct effects on the tumour epithelial cells within those tumours in which there is also extravascular expression of the Tie1 receptor tyrosine kinase.

[1]  T. Ludwig.  Local proteolytic activity in tumor cell invasion and metastasis. , 2005, BioEssays : news and reviews in molecular, cellular and developmental biology.

[2]  H. Augustin,et al.  Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2 , 2005, The Journal of cell biology.

[3]  P. Bonnier,et al.  Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. , 2005, International journal of oncology.

[4]  C. Tait,et al.  Angiopoietins in tumours: the angiogenic switch , 2004, The Journal of pathology.

[5]  A. Miyauchi,et al.  Tie‐1 tyrosine kinase expression in human thyroid neoplasms , 2004, Histopathology.

[6]  C. Livasy,et al.  Overexpression of the Receptor Tyrosine Kinase Tie-1 Intracellular Domain in Breast Cancer , 2003, Tumor Biology.

[7]  Siqing Shan,et al.  Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Marron,et al.  The Antiinflammatory Endothelial Tyrosine Kinase Tie2 Interacts With a Novel Nuclear Factor-&kgr;B Inhibitor ABIN-2 , 2003, Circulation research.

[9]  P. Bonnier,et al.  Tie2/Tek expression in breast carcinoma: correlations of immunohistochemical assays and long-term follow-up in a series of 909 patients. , 2003, International journal of oncology.

[10]  J. York,et al.  The Endothelial Receptor Tyrosine Kinase Tie1 Activates Phosphatidylinositol 3-Kinase and Akt To Inhibit Apoptosis , 2002, Molecular and Cellular Biology.

[11]  M. Marron,et al.  Vascular endothelial growth factor modulates the Tie-2:Tie-1 receptor complex. , 2002, Microvascular research.

[12]  S. Lo,et al.  Tie-1 tyrosine kinase is an independent prognostic indicator for invasive breast cancer. , 2001, Anticancer research.

[13]  K. Alitalo,et al.  Tie receptors: new modulators of angiogenic and lymphangiogenic responses , 2001, Nature Reviews Molecular Cell Biology.

[14]  M. Marron,et al.  Evidence for Heterotypic Interaction between the Receptor Tyrosine Kinases TIE-1 and TIE-2* , 2000, The Journal of Biological Chemistry.

[15]  J. Kim,et al.  Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. , 2000, Circulation research.

[16]  W Y Lui,et al.  tie-1 protein tyrosine kinase: a novel independent prognostic marker for gastric cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  M. McCarthy,et al.  Potential roles of metalloprotease mediated ectodomain cleavage in signaling by the endothelial receptor tyrosine kinase Tie-1. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[18]  H. Yamane,et al.  HEMOSTASIS , THROMBOSIS , AND VASCULAR BIOLOGY Inflammatory Cytokines and Vascular Endothelial Growth Factor Stimulate the Release of Soluble Tie Receptor From Human Endothelial Cells Via Metalloprotease Activation , 1999 .

[19]  N. Copeland,et al.  Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Dewhirst,et al.  Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Duffy,et al.  Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review). , 1998, International journal of oncology.

[22]  D. Fishman,et al.  The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. , 1998, International journal of oncology.

[23]  D. Brankow,et al.  Regulation of tie receptor expression on human endothelial cells by protein kinase C-mediated release of soluble tie. , 1997, Blood.

[24]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[25]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[26]  J. Rossant,et al.  The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. , 1995, The EMBO journal.

[27]  Thomas N. Sato,et al.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.

[28]  E. Liu,et al.  Novel protein kinases expressed in human breast cancer , 1993, International journal of cancer.

[29]  J. Partanen,et al.  A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains , 1992, Molecular and cellular biology.

[30]  J. A. Matthews,et al.  Enhanced chemiluminescent method for the detection of DNA dot-hybridization assays. , 1985, Analytical biochemistry.

[31]  International Journal of Oncology , 2017 .

[32]  K. Rajashankar,et al.  Crystal structures of the Tie 2 receptor ectodomain and the angiopoietin-2 – Tie 2 complex , 2006 .

[33]  K. Rajashankar,et al.  Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2–Tie2 complex , 2006, Nature Structural &Molecular Biology.

[34]  M. Dewhirst,et al.  Functional significance of Tie2 signaling in the adult vasculature. , 2004, Recent progress in hormone research.

[35]  A. Ullrich,et al.  Receptor tyrosine kinases as targets for anticancer drugs. , 2002, Trends in molecular medicine.

[36]  S. Ziegler,et al.  Molecular cloning and characterization of a novel receptor protein tyrosine kinase from human placenta. , 1993, Oncogene.